Cargando…
Framework of Intrinsic Immune Landscape of Dormant Prostate Cancer
Androgen deprivation therapy (ADT) is the standard therapy for men with advanced prostate cancer (PCa). PCa often responds to ADT and enters a dormancy period, which can be recognized clinically as a minimal residual disease. However, the majority of these patients will eventually experience a relap...
Autores principales: | Wong, Nelson K. Y., Dong, Xin, Lin, Yen-Yi, Xue, Hui, Wu, Rebecca, Lin, Dong, Collins, Colin, Wang, Yuzhuo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105276/ https://www.ncbi.nlm.nih.gov/pubmed/35563856 http://dx.doi.org/10.3390/cells11091550 |
Ejemplares similares
-
miR-100-5p inhibition induces apoptosis in dormant prostate cancer cells and prevents the emergence of castration-resistant prostate cancer
por: Nabavi, Noushin, et al.
Publicado: (2017) -
Influence of ADT on B7-H3 expression during CRPC progression from hormone-naïve prostate cancer
por: Kang, Ning, et al.
Publicado: (2023) -
Next generation patient-derived prostate cancer xenograft models
por: Lin, Dong, et al.
Publicado: (2014) -
Modeling Androgen Deprivation Therapy–Induced Prostate Cancer Dormancy and Its Clinical Implications
por: Dong, Xin, et al.
Publicado: (2022) -
Aneustat (OMN54) has aerobic glycolysis‐inhibitory activity and also immunomodulatory activity as indicated by a first‐generation PDX prostate cancer model
por: Qu, Sifeng, et al.
Publicado: (2018)